Semaglutide's CVD indication could cost US Medicare $145bn extra a year.
作者信息
Mahase Elisabeth
机构信息
The BMJ.
出版信息
BMJ. 2024 Aug 28;386:q1878. doi: 10.1136/bmj.q1878.
PMID:39197936
Abstract
摘要
相似文献
1
Semaglutide's CVD indication could cost US Medicare $145bn extra a year.司美格鲁肽的心血管疾病适应症可能使美国医疗保险每年额外花费1450亿美元。
BMJ. 2024 Aug 28;386:q1878. doi: 10.1136/bmj.q1878.
2
Estimating New Eligibility and Maximum Costs of Expanded Medicare Coverage of Semaglutide for Cardiovascular Risk Prevention.估算司美格鲁肽扩大医保覆盖范围用于心血管疾病风险预防的新增资格标准和最高费用
Ann Intern Med. 2024 Oct;177(10):1440-1442. doi: 10.7326/ANNALS-24-00308. Epub 2024 Aug 27.
3
Prescription Fills for Semaglutide Products by Payment Method.按支付方式划分的司美格鲁肽产品处方配药情况
JAMA Health Forum. 2024 Aug 2;5(8):e242026. doi: 10.1001/jamahealthforum.2024.2026.
4
Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.口服司美格鲁肽与注射用胰高血糖素样肽-1 受体激动剂：控制成本分析。
J Med Econ. 2020 Jun;23(6):650-658. doi: 10.1080/13696998.2020.1722678. Epub 2020 Feb 7.
5
Oral Semaglutide (Rybelsus) for the Treatment of Type 2 Diabetes Mellitus.口服司美格鲁肽（Rybelsus）用于治疗2型糖尿病
Am Fam Physician. 2020 Nov 15;102(10):627-628.
6
Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.评估口服司美格鲁肽治疗达标患者的人均成本：美国短期成本效益分析。
Adv Ther. 2019 Dec;36(12):3483-3493. doi: 10.1007/s12325-019-01125-y. Epub 2019 Oct 24.
7
The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.在斯洛伐克，每周一次司美格鲁肽与每周一次度拉鲁肽治疗 2 型糖尿病的管理：一项长期成本效益分析。
Adv Ther. 2019 Aug;36(8):2034-2051. doi: 10.1007/s12325-019-00965-y. Epub 2019 Jun 5.
8
Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study.在真实世界环境中，与基础胰岛素相比，初治 2 型糖尿病患者接受度拉鲁肽治疗的临床和经济结局：DISPEL 研究。
BMJ Open Diabetes Res Care. 2019 Dec 9;7(1):e000884. doi: 10.1136/bmjdrc-2019-000884. eCollection 2019.
9
Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.口服司美格鲁肽添加到当前抗高血糖治疗方案用于 2 型糖尿病的成本效果分析。
J Manag Care Spec Pharm. 2021 Apr;27(4):455-468. doi: 10.18553/jmcp.2021.27.4.455.
10
Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.每周一次司美格鲁肽治疗 2 型糖尿病患者：荷兰的成本效益分析。
BMJ Open Diabetes Res Care. 2019 Oct 1;7(1):e000705. doi: 10.1136/bmjdrc-2019-000705. eCollection 2019.
Zotero 插件